Stories
» Go to news mainWhat's New in Y‑90?
Technical and procedural innovations in Y-90 radioembolization including existing and investigational next-generation technologies.
Yttrium-90 (Y-90) transarterial radioembolization (TARE), also known as selective internal radiation therapy (SIRT), has been used for the treatment of primary and secondary liver cancer for decades. This therapy has greatly advanced since the seminal publications on the clinical, technical, and procedural aspects of Y-90 therapy.1-3 Numerous subsequent studies have confirmed the safety and efficacy of Y-90 therapy, resulting in significant growth in its use. Multidisciplinary recognition of the value of Y-90 therapy is highlighted by its inclusion in the National Comprehensive Cancer Network guidelines as a category 2A recommended therapy for colon and rectal cancer liver metastases.4 This, as well as a key institution’s multidisciplinary team’s decision to choose Y-90 as first-line therapy for hepatocellular carcinoma (HCC),5 should lead to continued growth and adoption. This article describes technical and procedural innovations in Y-90 radioembolization and introduces promising next-generation investigational technologies for this well-established and effective therapy.
Recent News
- QEII welcomes the first GE StarGuide SPECT‑CT scanner in Canada.
- The first 68Ga‑PSMA PET scans in Atlantic Canada mark a new era in prostate cancer assessment
- Dr. David Volders awarded the Dr. Charles Lo Prize in Radiology Research
- Radiology Research Day 2024
- Program Administrator Award of Excellence
- Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update
- Dr. Siân Iles interviewed on CBC's Information Morning
- Dr. Steven Beyea and Dr. Adela Cora featured in the latest Beyond Research podcast from ResearchNS
Comments
comments powered by Disqus